Quetiapine Fumarate XR Tablets
Awarded on September 7, 2023. Full description on SAM.gov.
Overview
- Posted
- October 7, 2026
- Notice type
- Award Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDEFENSE LOGISTICS AGENCY
Notice details
- Office
- TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT
- Place of performance
- Hauppauge, New York, 11788
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
- Award date
- Sep 7, 2023
- Award amount (SAM.gov award notice)
- $4.3M
Identifiers
- Solicitation number
- SPE2D223D0012
- Notice ID
- 99d39fb9459d489089749fa826ed4021
- Award number (PIID)
- SPE2D223D0012
Description
Modification SPE2D223D0012 P00009 to exercise Option Year 3.
Award Overview
Award Number
SPE2D223D0012
Award Amount (SAM.gov award notice)
$4.3M
Award Date
Sep 7, 2023
Awardee
Awardee UEI
GQLDJJ8AQNN5
Awardee CAGE Code
1HT23
Awardee Address
Camarillo, CA 93012, UNITED STATES
Line Item Number
SPE2D223D0012
Original Solicitation
Notice ID: 99d39fb9459d489089749fa826ed4021
Posted Date: Oct 7, 2026
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- $147.36Signed Aug 12, 2026
- $535.44Signed Aug 12, 2026
- $27.3Signed Aug 12, 2026
- $85.96Signed Aug 10, 2026
- $133.86Signed Aug 7, 2026
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (10)
- Download
MOD P00009 - Option Year 3.PDF.pdf
18 KBAdded in Award Notice version 7Posted - Download
MOD P00006 - Option Year Two - 18.Oct.2025 to 17.Oct.2026.pdf
18 KBAdded in Award Notice version 7Posted - Download
Signed MOD P0004 - Exercising Option 1 - Quetiapine Fumarate XR.pdf
113 KBAdded in Award Notice version 5Posted - Download
Amendment 0003 SPE2D2-23-R-0010.pdf
333 KBAdded in Solicitation version 5Posted - Download
Signed SPE2D223D0012 P00002 Quetiapine Fumarate XR.pdf
117 KBAdded in Award Notice version 4Posted - Download
Amendment 0002 SPE2D2-23-R-0010.pdf
18 KBAdded in Solicitation version 4Posted - Download
Signed SPE2D223D0012 P00001.pdf
1009 KBAdded in Award Notice version 3Posted - Download
Amendment 0001 SPE2D2-23-R-0010.pdf
323 KBAdded in Solicitation version 3Posted - Download
Signed Award SPE2D2-23-D-0012 Quetiapine Fumarate XR Tablets.pdf
12 MBAdded in Award Notice version 2Posted - Download
Quetiapine Fumarate XR Tablets National Contract Solicitation SPE2D223R0010.pdf
1.4 MBAdded in Solicitation version 2Posted
Lifecycle
- 1Version 1Solicitation
Quetiapine Fumarate XR Tablets
- 2Version 2Award Notice
Type changed from Solicitation to Award Notice
Quetiapine Fumarate XR Tablets
- 3Version 3Award Notice
Quetiapine Fumarate XR Tablets
- 4Version 4Award Notice
Quetiapine Fumarate XR Tablets
- 5Version 5Award Notice
Quetiapine Fumarate XR Tablets
- 6Version 6Award Notice
Quetiapine Fumarate XR Tablets
- 7Version 7Award NoticeCurrent
Quetiapine Fumarate XR Tablets
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
SPE2D2-26-D-0004 Morphine IR & ER Tablets Award | - | Awarded | Open |
Modification P00010 SPE2D223D0002 is issued to invoke option year 4 for Bupropion HCL ER National Contract. Modification P00009 SPE2D223D0002 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026). Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract. Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation. Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract. Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation. NATIONAL CONTRACT SPE2D2-23-D-0002 BUPROPION HCL ER | - | Awarded | Open |
MOD for Option Year Two (2) is attached. | - | Awarded | Open |
Modification to exercise option year 1. | - | Awarded | Open |
1. Option #1 is hereby executed for the period July 2, 2026 through July 1, 2027. 2. All other terms and conditions remain unchanged. | - | Awarded | Open |
Additional Details
Solicitation Number
SPE2D223D0012
Archive Date
Oct 17, 2029
Office Address
PHILADELPHIA, PA, 19111